Last reviewed · How we verify
Leptryl (PERIMETAZINE)
Leptryl (generic name: PERIMETAZINE) is a drug. It is currently in Phase 2 development.
Leptryl works by interacting with a specific molecular target to produce its therapeutic effect.
Leptryl (Perimetazine) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Leptryl is owned by an unspecified company, and its generic status is uncertain. Further research is needed to understand its clinical applications and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | PERIMETAZINE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and Leptryl has a key that fits into those locks. When it binds to the lock, it helps to regulate the cell's activity, which can help to treat certain conditions. This is a simplified explanation of how Leptryl works at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leptryl CI brief — competitive landscape report
- Leptryl updates RSS · CI watch RSS
Frequently asked questions about Leptryl
What is Leptryl?
How does Leptryl work?
What is the generic name of Leptryl?
What development phase is Leptryl in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing